Informasjon

Behandling av leddgikt

Behandling av leddgikt kan mildne sykdomsforløpet. Den foretrukne medikamentgruppen betegnes DMARDs, såkalte sykdomsmodifiserende medisiner.

Vil du vite mer?

Norsk Revmatikerforbund
Årsaker til leddgikt
Symptomer ved leddgikt
Påvisning av leddgikt
Behandling av leddgikt
Graviditet i forbindelse med leddgikt
Juvenil revmatoid artritt
Revmatoid artritt - for helsepersonell
Juvenil revmatoid artritt - for helsepersonell

Vil du vite mer?

Få tilgang på artikkelen om dette temaet fra Legehandboka.no

Artikkelen inneholder all informasjon norske allmennleger bruker i sitt daglige arbeid.

Jeg har lest og akseptert Brukervilkår ved kjøp av NEL-dokumenter

Dette dokumentet er basert på det profesjonelle dokumentet "Revmatoid artritt". Referanselisten for dette dokumentet vises nedenfor.

Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Seminar. Lancet 2010; 376: 1094-1108. PubMed
Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2011; 84: 1245-52. American Family Physician
Balsa A, Cabezón A, Orozco G, et al. Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther 2010; 12: 62. PubMed
McClure A, Lunt M, Eyre S, et al. Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. Rheumatology (Oxford) 2009; 48: 1369-74. PubMed
Schett G, Firestein GS. Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 787-9. PubMed
McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42. PubMed
Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98. PubMed
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2010; 365: 2205-19. PubMed
MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; 43: 30-7. PubMed
Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006; 119: 503 e1-9.
Bang SY, Lee KH, Cho SK, et al. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status. Arthritis Rheum 2010; 62: 369-77. PubMed
Karlson EW, Mandl LA, Hankinson SE, et al. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study. Arthritis Rheum 2004; 50: 3458-467. PubMed
Mikuls TR, Payne JB, Reinhardt RA, et al. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol 2009; 9: 38-42. PubMed
Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-9. PubMed
Aletaha D, Neogi T, Silman AJ. 2010 Rheumatoid arthritis classification criteria. An American College of Rehumatology/Europena League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2010; 62: 2569-81. PubMed
Nishimura K, Sugiyama D, Kogata Y et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797-808. PubMed
Payet J, Goulvestre C, Biale L, et al. Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients. J Rheumatol. 2014 Oct 1. pii: jrheum.131375. PMID: 25274898. PubMed
Nielsen SF, Bojesen SE, Schnohr P, Nordestgaard BG. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 2012; 345: e5244. doi:10.1136/bmj.e5244 DOI
Ravelli A, Felici E, Magni-Manzoni S, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005; 52: 826-32. PubMed
Wilson A, Yu HT, Goodnough LT, et al. Prevalence and outcomes of anemia in rheumatoid arthritis. Am J Med 2004; 116(suppl 7A): 50S-57S.
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328-46. PubMed
Emanuel G, Charlton J, Ashworth M, et al. Cardiovascular risk assessment and treatment in chronic inflammatory disorders in primary care . Heart 2016; 102: 1957-62. pmid:27534979 PubMed
McQueen FM, Benton N, Crabbe J, Robinson E, Yeoman S, McLean L, et al. What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x-rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis 2001; 60: 859-68. PubMed
Lindegaard HM, Hørslev-Petersen K, Junker P. Hurtig henvisning og behandling af patienter med akut artritis. Ugeskr Læger 2005; 167: 4458-61. Ugeskrift for Læger
Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34-45. PubMed
Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilosen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894-8. PubMed
Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516-28. doi: 10.1136/annrheumdis-2013-204577 DOI
Singh JA, Saag KG, Bridges Jr. SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2015; doi: 10.1002/art.39480 DOI
Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017. pmid:28264816 PubMed
Scott DL, Ibrahim F, Farewell V, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015; 350: h1046. doi:10.1136/bmj.h1046 DOI
Iannone F, Lopalco G, Cantarini L, et al. Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. Clin Rheumatol. 2016 Jan;35(1):19-23. Epub 2015 Nov 19. pmid: 26581205 PubMed
Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 2016; 353: i1777. doi:10.1136/bmj.i1777 DOI
Hollan I, Mikkelsen K, Førre Ø. Revmatoid artritt - en risikofaktor for iskemisk hjertesykdom. Tidsskr Nor Lægeforen 2005; 125: 3259-62. PubMed
Durcan L, Wilson F, Cunnane G. The Effect of Exercise on Sleep and Fatigue in Rheumatoid Arthritis: A Randomized Controlled Study. J Rheumatol. 2014 Aug 15. pii: jrheum.131282
Rongen-van Dartel SA, Repping-Wuts H, Flendrie M, et al. Effect of Aerobic Exercise Training on Fatigue in Rheumatoid Arthritis: A Meta-Analysis. Arthritis Care Res (Hoboken) 2015; 67: 1054-62. doi:10.1002/acr.22561 DOI
Proudman SM, James MJ, Spargo LD, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis. 2013 Sep 30. PMID: 24081439 PubMed
Tedeschi SK, Bathon JM, Giles JT, et al. Relationship Between Fish Consumption and Disease Activity in Rheumatoid Arthritis. Arhtritis Care Res (Hoboken) 2018; 70: 327-32. pmid:28635117 PubMed
Stolt P, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003; 62: 835-41. PubMed
Westhoff G, Rau R, Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology 2008; 47: 849-54. Rheumatology
Mattey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol 2009; 36: 1180-7. PubMed
Gonzalez A, Maradit Kremers H, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 2008; 67: 64-9. PubMed
Riemsma RP, Kirwan JR, Taal E, Rasker HJJ. Patient education for adults with rheumatoid arthritis. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD003688. DOI: 10.1002/14651858.CD003688 DOI
Deighton C, O'Mahony R, Tosh J, et al.; Guideline Development Group. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009; 338: b702. BMJ (DOI)
Boers M. Rheumatoid arthritis. Treatment of early disease. Rheum Dis Clin North Am 2001; 27: 405-14,x.
Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167-79. New England Journal of Medicine
Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 124-34. Annals of Internal Medicine
O'Dell JR, Mikulus TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013. doi:10.1056/NEJMoa1303006 DOI
Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD000957. DOI: 10.1002/14651858.CD000957.pub2 DOI
Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82. PubMed
Tilstra JS, Lienesch DW. Rheumatoid Nodules. Dermatol Clin. 2015;33(3):361-71 PubMed
Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD000951. DOI: 10.1002/14651858.CD000951.pub2 DOI
Scott DL. Leflunomide improves quality of life in Rheumatoid Arthritis. Scand J Rheumatol 1999; suppl.112:23-9.
Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells GA, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD000959. DOI: 10.1002/14651858.CD000959. DOI
Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507. New England Journal of Medicine
van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19. New England Journal of Medicine
Burmester GR, Blanco R, Charles-Schumann C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate respons to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60. PubMed
Lee EB, Fleischmann R, GHalls S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014 Jun 19; 370:2377. PMID: 24941177 PubMed
Xie F, Yun H, Bernatsky S, Curtis JR. Risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol 2016; 68: 2612. pmid:27213279 PubMed
Statens legemiddelver. Nyheter. Økt risiko for blodpropp i lungene og død ved behandling med høyere dose tofacitinib (Xeljanz). Publisert: 26.03.2019. legemiddelverket.no
Felleskatalogen. Xeljanz. Siden besøkt 01.04.2019. www.felleskatalogen.no
Perrot S, Javier RM, Marty M, Le Jeunne C, Laroche F; CEDR (Cercle d'Etude de la Douleur en Rhumatologie France), French Rheumatological Society, Pain Study Section. Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies. Rheumatology 2008; 47: 1117-23. Rheumatology
Leumbruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136-45. PubMed
Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015. doi: 10.1016/S0140-6736(14)61704-9. DOI
Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017. pmid:28298374 PubMed
Berset IP, Klemp M, Jahnsen, et al. Nasjonale faglige retningslinjer for bruk av TNF-α hemmere og andre biologiske betennelsesdempende legemidler innen revmatologi, gastroenterologi og dermatologi. Helsedirektoratet. Revidert utgave februar 2010
Førre Ø, Haugen M, Hassfeldt WG. New treatment possibilities in rheumatoid arthritis. Scand J Rheumatol 2000;29:73-84. PubMed
Michaud TLRho YHShamliyan TKuntz KMChoi HK. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014 Dec;127(12):1208-32 . doi:10.1016/j.amjmed.2014.06.012 DOI
Lethaby A, Lopez-Olivo MA, Maxwell LJ, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD004525. DOI: 10.1002/14651858.CD004525.pub2. DOI
Paul Emery, Mohammed Hammoudeh, Oliver FitzGerald, et al. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. NJEM 2014; 371: 1781-92. doi:10.1056/NEJMoa1316133 DOI
Weinblatt ME, Westhovens R, Mendelsohn AM, et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis 2013 Sep 3
Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritits on the basis of achievement of stable low disease activity with adalimumab plus methotrexate og methotrexate alone, the randomised controlled OPTIMA trial. Lancet 2013. doi:10.1016/S0140-6736(13)61751-1 DOI
Bijlsma JWJ, Welsing PMJ, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): A multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 2016 doi: 10.1016/S0140-6736(16)30363-4 DOI
Nuki G, Breshnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 2838-46. PubMed
Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (study evaluating rituximab's efficacy in mtx inadequate responders (serene)). Ann Rheum Dis 2010; 69: 1629-35. PubMed
Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD007356. DOI: 10.1002/14651858.CD007356.pub2 DOI
Kirwan JR, Bijlsma JWJ, Boers M, Shea B. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD006356. DOI: 10.1002/14651858.CD006356. DOI
Best JH, Kong AM, Lenhart GM, et al. Association between glucocorticoid exposure and healthcare expenditures for potential glucocorticoid-related adverse events in patients with rheumatoid arthritis. J Rheumatol 2018. pmid:29335343 PubMed
Brodin N, Eurenius E, Jensen I, et al. Coaching patients with early rheumatoid arthritis to healthy physical activity. Arthritis Rheum 2008; 59: 325-31. PubMed
Baillet A, Payraud E, Niderprim VA, et al. A dynamic exercise programme to improve patients' disability in rheumatoid arthritis: a prospective randomized controlled trial. Rheumatology (Oxford) 2009; 48: 410-15. PubMed
Welch V, Brosseau L, Casimiro L, Judd M, Shea B, Tugwell P, Wells GA. Thermotherapy for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002826. DOI: 10.1002/14651858.CD002826. The Cochrane Library
Jemtland Enger K, Bjørnstad K, Rødevand E, Skomsvoll JF. Effekt av trening på smerte ved revmatoid artritt. Tidsskr Nor Lægeforen 2003; 123: 1508-10. PubMed
Hurkmans E, van der Giesen FJ, Vliet Vlieland TPM, Schoones J, Van den Ende ECHM. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD006853. PMID: 19821388 PubMed
Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripetygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis. A randomized trial. Ann Intern Med 2009; 151: 229-40. Annals of Internal Medicine
Cameron M, Gagnier JJ, Chrubasik S. Herbal therapy for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.: CD002948. DOI: 10.1002/14651858.CD002948.pub2 DOI
Egan M, Brosseau L, Farmer M, Ouimet MA, Rees S, Tugwell P, Wells GA. Splints and Orthosis for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD004018. DOI: 10.1002/14651858.CD004018 DOI
Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2018. pmid:29572291 PubMed
Chung CP, Sokka T, Arbogast PG, Pincus T. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis. 2006; 65: 1653-7. PubMed
Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62:722-7. PubMed
Meune C, Touze E, Trinquart L, et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2009; 48: 1309-13. Rheumatology
Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74: 480-9. doi: 10.1136/annrheumdis-2014-206624 DOI
Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929-34. PubMed
Mantel A, Holmqvist M, Andersson DC et al. Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure. J Am Coll Cardiol 2017; 69(10): 1275-85. pmid:28279294 PubMed
Guillemin F, Gerard N, van Leeuwen M, Smedstad LM, Kvein TK, van den Heuvel W, et al. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. J Rheumatol 2003; 30: 2585-9. PubMed
Atzeni F, Turiel M, Caporali R, et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010; 9: 835-9. PubMed
Terslev L, Danneskiold-Samsøe B. Graviditet i forbindelse med reumatoid artrit. Ugeskr Læger 2003; 165: 3077-81. PubMed

Meld deg på nyhetsbrev

Er du helsepersonell?

Ved å oppgi dette kan du få bedre tilpasset innhold om du har formell helsefaglig kompetanse

Annonsørinnhold

Annonsørinnhold fra SOBI

Hvorfor blir penis bøyd?

Ingen penis er helt rett når den er erigert. Dette varierer fra mann til mann og vinkelen påvirker vanligvis ikke sexlivet, humøret eller selvtilliten. Ved Peyronies sykdom kan krumningen bli så stor at det kan by på problemer. Da finnes det hjelp å få.

Mest lest i dag

Lunger

Behandling av leddgikt

Hopp til innhold

Vil du vite mer?

Er du helsepersonell?

Annonsørinnhold

Hvorfor blir penis bøyd?

Mest lest i dag

Lungefibrose

Borreliose etter flåttbitt

Akutte smerter i siden, flankesmerter

Behandling av leddgikt

Hopp til innhold

Vil du vite mer?

Er du helsepersonell?

Andre leste også dette

Legemidler ved leddgikt

Leddgikt og graviditet

Påvisning av leddgikt

Annonsørinnhold

Hvorfor blir penis bøyd?

Mest lest i dag

Lungefibrose

Borreliose etter flåttbitt

Akutte smerter i siden, flankesmerter